Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Kvβ1.1 subunit, encoded by the KCNAB1 gene, is a critical auxiliary component of voltage-gated potassium (Kv) channels, particularly those in the Shaker-related (Kv1) family [1, 3]. Located in the cytoplasm, it forms heteromultimeric complexes with pore-forming alpha-subunits to modulate their functional properties, most notably by conferring rapid N-type (fast) inactivation [4, 5]. This 'ball-and-chain' mechanism allows the subunit to physically obstruct the channel pore, thereby regulating the duration and frequency of action potentials in excitable tissues [2, 7]. In the heart, Kvβ1.1 plays a vital role in maintaining electrical stability and repolarization; its absence or dysfunction has been linked to cardiac hypertrophy and increased susceptibility to arrhythmias [6]. In the central nervous system, it fine-tunes neuronal excitability, with genetic variations associated with conditions such as epilepsy and episodic ataxia [1, 8]. Beyond its regulatory role, Kvβ1.1 possesses aldo-keto reductase activity and binds NADPH, which further influences its ability to modulate channel gating in response to the cellular redox state [4, 12]. As a therapeutic target, it is being explored for the development of small molecule modulators to treat hyperexcitability disorders [8, 9]. It also serves as a genetic biomarker for predicting drug-induced toxicities, such as bevacizumab-induced hypertension [1, 15]. The subunit's ability to integrate metabolic signals with electrical activity makes it a unique focus for cardiovascular and neurological research [11, 13]. Overall, Kvβ1.1 is a key regulator of cellular excitability with significant implications for disease pathogenesis and drug safety.
Modulation of alpha-beta subunit protein-protein interactions and inhibition of N-type inactivation to regulate channel gating and neuronal/cardiac excitability.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-gated potassium channel subunit beta-1 (KCNAB1) (Kvβ1.1).